Rapid Analysis of Drugs: A Pilot Surveillance System To Detect Changes in the Illicit Drug Supply To Guide Timely Harm Reduction Responses - Eight Syringe Services Programs, Maryland, November 2021-August 2022 - PubMed
- ️Sun Jan 01 2023
. 2023 Apr 28;72(17):458-462.
doi: 10.15585/mmwr.mm7217a2.
- PMID: 37104171
- DOI: 10.15585/mmwr.mm7217a2
Free article
Rapid Analysis of Drugs: A Pilot Surveillance System To Detect Changes in the Illicit Drug Supply To Guide Timely Harm Reduction Responses - Eight Syringe Services Programs, Maryland, November 2021-August 2022
Erin Russell et al. MMWR Morb Mortal Wkly Rep. 2023.
Free article
Abstract
A record number of 2,912 drug overdose deaths occurred in Maryland during the 12-month period July 1, 2020-June 30, 2021. Illicitly manufactured fentanyl, fentanyl analogs, or both* were involved in 84% of these deaths.† Timely identification of illicit drug market changes (e.g., fentanyl rapidly replacing heroin) could improve the public health response, specifically communications about risks for novel psychoactive substances. During November 19, 2021-August 31, 2022, the National Institute of Standards and Technology (NIST)§ tested 496 deidentified drug paraphernalia samples that staff members collected at eight Maryland syringe services programs (SSPs), also known as needle exchange programs,¶ in partnership with the Maryland Department of Health Center for Harm Reduction Services (CHRS).** All test results were available within 48 hours. Among the 496 paraphernalia samples collected, 367 (74.0%) tested positive for an opioid, and 364 (99.2%) of these samples contained fentanyl or fentanyl analogs. Approximately four fifths of fentanyl-positive samples also tested positive for the veterinary medicine xylazine, a sedative that when combined with opioids might increase the potential for fatal respiratory depression and soft tissue infections when injected (1). For 248 of the 496 samples, SSP participants also completed a questionnaire about the drugs they had intended to purchase. Among the 212 participants who had intended to buy an opioid, 87.7% were exposed to fentanyl, fentanyl analogs, or both, and 85.8% were unknowingly exposed to xylazine. Results improved awareness of fentanyl and xylazine among SSP staff members and galvanized efforts to enhance SSPs' wound care services for participants experiencing soft tissue injuries possibly associated with injecting xylazine. Rapid analysis of drug paraphernalia can provide timely data on changing illicit drug markets that can be used to mitigate the harms of drug use more effectively.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Margaret Rybak reports contract employment with the CDC Foundation under the Overdose Data to Action Grant. Jasmine Lopes reports contract employment with the CDC Foundation under the Overdose Data to Action Grant. No other potential conflicts of interest were disclosed.
Similar articles
-
Bradford W, Figgatt M, Scott KS, Marshall S, Eaton EF, Dye DW. Bradford W, et al. Harm Reduct J. 2024 Feb 20;21(1):46. doi: 10.1186/s12954-024-00959-2. Harm Reduct J. 2024. PMID: 38378660 Free PMC article.
-
Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review.
D'Orazio J, Nelson L, Perrone J, Wightman R, Haroz R. D'Orazio J, et al. Ann Intern Med. 2023 Oct;176(10):1370-1376. doi: 10.7326/M23-2001. Epub 2023 Oct 10. Ann Intern Med. 2023. PMID: 37812779 Review.
-
Collins AB, Wightman RS, Macon EC, Guan Y, Shihipar A, Krieger M, Elmaleh R, Smith MC, Morales A, Badea A. Collins AB, et al. Int J Drug Policy. 2023 Aug;118:104118. doi: 10.1016/j.drugpo.2023.104118. Epub 2023 Jul 7. Int J Drug Policy. 2023. PMID: 37422985
-
Zibbell JE, Peiper NC, Duhart Clarke SE, Salazar ZR, Vincent LB, Kral AH, Feinberg J. Zibbell JE, et al. Int J Drug Policy. 2021 Jul;93:103128. doi: 10.1016/j.drugpo.2021.103128. Epub 2021 Jan 22. Int J Drug Policy. 2021. PMID: 33487527
-
Zhu DT. Zhu DT. Harm Reduct J. 2023 Sep 12;20(1):131. doi: 10.1186/s12954-023-00867-x. Harm Reduct J. 2023. PMID: 37700329 Free PMC article. Review.
Cited by
-
German D, Genberg B, Sugarman O, Saloner B, Sawyer A, Glick JL, Gribbin M, Flynn C. German D, et al. Harm Reduct J. 2024 Jan 22;21(1):18. doi: 10.1186/s12954-024-00940-z. Harm Reduct J. 2024. PMID: 38254198 Free PMC article.
-
Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022.
Cano M, Daniulaityte R, Marsiglia F. Cano M, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2350630. doi: 10.1001/jamanetworkopen.2023.50630. JAMA Netw Open. 2024. PMID: 38180756 Free PMC article.
-
Hauschild MH, Warp PV, Tookes HE, Yakir E, Malhotra B, Malik S, Owens C, Suarez E Jr, Serota DP, Bartholomew TS. Hauschild MH, et al. Drug Alcohol Depend Rep. 2023 Dec 5;9:100209. doi: 10.1016/j.dadr.2023.100209. eCollection 2023 Dec. Drug Alcohol Depend Rep. 2023. PMID: 38162510 Free PMC article.
-
Park JN, Serafinski R, Ujeneza M, McKenzie M, Tardif J, Krotulski AJ, Badea A, Grossman ER, Green TC. Park JN, et al. Drug Alcohol Depend Rep. 2024 Jun 5;11:100247. doi: 10.1016/j.dadr.2024.100247. eCollection 2024 Jun. Drug Alcohol Depend Rep. 2024. PMID: 38974777 Free PMC article.
-
Wildenthal JA, Schwartz DJ, Nolan NS, Zhao L, Robinson JI, Jones E, Jawa R, Henderson JP, Marks LR. Wildenthal JA, et al. Open Forum Infect Dis. 2023 Dec 11;11(1):ofad628. doi: 10.1093/ofid/ofad628. eCollection 2024 Jan. Open Forum Infect Dis. 2023. PMID: 38179104 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources